复发性子宫内膜癌的综合基因组图谱分析:对系统治疗选择的意义
本研究对74例复发性子宫内膜癌患者的存档组织行基于杂交捕获的基因组图谱分析,以POLE突变、错配修复状态和p53突变作为拷贝数状态的替代指标,将全部病例分为四个TCGA分子亚组;91%(67/74)检出至少一个临床相关基因组改变,32%(24/74)接受匹配治疗,客观缓解率25%(6/24),临床获益率62.5%,中位治疗持续时间14.6个月(范围4.3-69个月)。
要点
- 综合基因组图谱可将复发性子宫内膜癌分为四个TCGA分子亚组。
- 91%(67/74)的肿瘤检出至少一个临床相关基因组改变。
- 32%(24/74)接受匹配治疗,客观缓解率25%(6/24)。
核心结论
- 综合基因组图谱可在常规临床诊疗中将子宫内膜癌分为四个TCGA类别,并识别匹配治疗的潜在生物标志物。
研究设计与样本
- 前瞻性分析74例复发性子宫内膜癌患者的存档组织,采用基于杂交捕获的基因组图谱分析,检测肿瘤突变负荷和微卫星不稳定性。
主要发现
- 以POLE突变分析、错配修复状态和p53突变分析作为拷贝数状态的替代指标,综合基因组图谱将全部病例归入四个TCGA分子亚组。
- 复发性浆液性子宫内膜癌以拷贝数高型为主,子宫内膜样、透明细胞和未分化肿瘤中未发现特定分子亚型的明确优势分布。
- 每个肿瘤样本均检出至少一个基因组改变,91%(67/74)检出至少一个临床相关基因组改变。
- 32%(24/74)的患者基于综合基因组图谱结果接受匹配治疗,客观缓解率为25%(6/24),另有37.5%(9/24)达到疾病稳定,临床获益率为62.5%,中位治疗持续时间为14.6个月(范围4.3-69个月)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To assess whether comprehensive genomic profiling (CGP) in the setting of routine clinical care allows molecular classification of recurrent endometrial cancer (EC) into the four Cancer Genome Atlas (TCGA) categories: POLE ultramutated, microsatellite instable, copy-number low, and copy-number high and whether this approach can identify genomic alterations (GAs) which inform treatment decisions. METHODS: Archival tissues from 74 patients diagnosed with recurrent EC were prospectively analyzed using hybrid-capture-based genomic profiling. Tumor mutational burden and microsatellite instability were measured. Clinically relevant GAs (CRGAs) were defined as GAs associated with targeted therapies available on-label or in mechanism-driven clinical trials. RESULTS: Using POLE mutational analysis, mismatch repair status, and p53 mutational analysis as surrogate for 'copy-number' status CGP segregated all cases into four TCGA molecular subgroups. While recurrent serous ECs were predominantly copy-number high, we found no clear prevalence of a specific molecular subtype in endometrioid, clear cell or undifferentiated tumors. Every tumor sample had at least one GA and 91% (67/74) had at least one CRGA. In this series 32% (24/74) of patients received a matched therapy based on the results of CGP. Objective responses to the matched therapy were seen in 25% (6/24) of patients with an additional 37.5% (9/24) achieving stable disease leading to a clinical benefit rate of 62.5% with a median treatment duration of 14.6 months (range 4.3-69 months). CONCLUSIONS: CGP allows molecular classification of EC into four TCGA categories and allows identification of potential biomarkers for matched therapy in the setting of routine clinical care.
引用
- Prendergast EN, Holman LL, Liu AY, et al. Comprehensive genomic profiling of recurrent endometrial cancer: Implications for selection of systemic therapy. Gynecol Oncol. 2019. PMID: 31257009. doi:10.1016/j.ygyno.2019.06.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。